Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
Authors:
- Alexandre LugatALAlexandre Lugat
- Éric FrampasÉFÉric Frampas
- Yann TouchefeuYTYann Touchefeu
- Éric MiralliéÉMÉric Mirallié
- Maëlle Le BrasMBMaëlle Le Bras
- Hélène SenellartHSHélène Senellart
- Aurore RauscherARAurore Rauscher
- Vincent FleuryVFVincent Fleury
- Loïc CampionLoïc Campion
- Vincent RohmerVRVincent Rohmer
- Olivier-François CouturierOCOlivier-François Couturier
- Rachida LebtahiRLRachida Lebtahi
Open Access
Abstract
The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-11-LABX-0018-01)
- Pays de la Loire Regional Council (ANR-11-LABX-0018-01)
This publication has 44 references indexed in Scilit:
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine TumorsJournal of Nuclear Medicine, 2013
- High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumoursJournal of Medical Imaging and Radiation Oncology, 2012
- Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center StudyAmerican Journal of Roentgenology, 2011
- The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine TumorsAnnals of Surgery, 2010
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine TumorsNeuroendocrinology, 2009
- Somatostatin, cortistatin and their receptors in tumoursMolecular and Cellular Endocrinology, 2008
- Evolution of the Diffuse Neuroendocrine System – Clear Cells and Cloudy OriginsNeuroendocrinology, 2006
- Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989